Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Pfizer and Zhejiang Hisun to Invest $545 Million in Generic Drug JV

publication date: Feb 20, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Pfizer and Zhejiang Hisun Pharma will put $545 million of assets into their branded generics JV. The investment will consist of off-patent drugs, manufacturing sites and cash. Hisun will contribute $295 million of these assets for a 51% stake in the JV, while Pfizer’s portion will be $250 million for the remaining 49%. The two companies signed a MOU to set up the JV in June 2011, and they have now made progress by approving a framework agreement and releasing the financial commitments of each party. More details....

Stock Symbols: (NYSE: PFE) (SHA: 600267)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at this event:
 
 
Hope to see you there!
 
ChinaBio® Events
 
China Forum 2014

Frankfurt, Germany
November 2, 2014

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors